Preventive treatment with CGRP monoclonal antibodies restores brain stem habituation deficits and excitability to painful stimuli in migraine: results from a prospective case-control study

BACKGROUND & OBJECTIVES: Calcitonin gene-related peptide ligand/receptor (CGRP) antibodies effectively reduce headache frequency in migraine. It is understood that they act peripherally, which raises the question whether treatment merely interferes with the last stage of headache generation or,...

Descripción completa

Detalles Bibliográficos
Autores principales: Thiele, Anne, Klehr, Lara, Strauß, Sebastian, Angermaier, Anselm, Schminke, Ulf, Kronenbuerger, Martin, Naegel, Steffen, Fleischmann, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903683/
https://www.ncbi.nlm.nih.gov/pubmed/34895133
http://dx.doi.org/10.1186/s10194-021-01364-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903683/
https://www.ncbi.nlm.nih.gov/pubmed/34895133
http://dx.doi.org/10.1186/s10194-021-01364-x

Ejemplares similares